{
    "brief_title": "Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer",
    "phase": "",
    "drugs": "['Abemaciclib']",
    "drugs_list": [
        "Abemaciclib"
    ],
    "diseases": "['Metastatic Breast Cancer']",
    "diseases_list": [
        "Metastatic Breast Cancer"
    ],
    "enrollment": "",
    "inclusion_criteria": "inclusion criteria: \n\n Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.",
    "exclusion_criteria": "",
    "brief_summary": "The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.",
    "NCT_ID": "NCT03763604"
}